Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2623

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2623
---
 which we currently license and sublicense intellectual property or technology from third parties are complex,
and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation
disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology,
or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material
adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property
that we have sublicensed prevent or impair our ability to maintain our current sublicensing arrangements on commercially acceptable terms,
we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect
on our business, financial conditions, results of operations, and prospects.

In
addition, we may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, or any
other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such
activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in
valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our sublicensors
initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual
property that is sublicensed to us. It is possible that such infringement proceedings or defense activities may be less vigorous than
had we conducted them ourselves.

Our
collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop from our
use of blood and other tissue samples and other materials required for our research and development activities, which they provide to
us, or otherwise arising from the collaboration.

We
collaborate with several institutions, universities, medical centers, physicians and researchers in scientific matters and expect to
continue to enter into additional collaboration agreements. In certain cases, we do not have written agreements with these collaborators,
or the written agreements we have do may not cover all instances of medical development that are researched by the counterparty. If we
cannot successfully negotiate sufficient ownership and commercial rights to any inventions that result from our use of a third-party
collaborator’s materials, or if disputes arise with respect to the intellectual property developed with the use of a collaborator’s
samples, or data developed in a collaborator’s